Revance Therapeutics (RVNC)

$13.01 0.54 (4.33%)

16:00 EDT RVNC Stock Quote Delayed 30 Minutes

3 Healthcare Stocks to Sell in September Before They Crash & Burn

By Noah Bolton, InvestorPlace Contributor Sep 6, 2023

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and....

3 Very Oversold Biotech Stocks to Buy Right Now

3 Very Oversold Pharma Stocks to Buy Right Now

7 Healthcare Stocks to Make You the Millionaire Next Door

Volume:

Previous Close -

Market Cap 934.50M

PE Ratio -2.82

EPS -4.61

Volume (Avg. Vol.) 3.82M

Day's Range $12.23 - $13.07

52-Week Range $11.10 - $36.65

Dividend & Yield N/A (N/A)

RVNC Stock Predictions, Articles, and Revance Therapeutics News

From InvestorPlace
From the Web

3 Pharma Stocks That Will Mint Millionaires

By Larry Ramer, InvestorPlace Contributor Jan 30, 2023

These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters.

Why Is Revance Therapeutics (RVNC) Stock Soaring Today?

By Larry Ramer, InvestorPlace Contributor Sep 8, 2022

RVNC stock is jumping 12% after the FDA approved its alternative to AbbVie's Botox. Revance's injection is supposed to last longer than Botox.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Oct 18, 2021

Welcome back, trader! I hope the weekend served you well because we've got pre-market stock movers to start off Monday with!

10 Monster Growth Stocks to Buy for 2019 and Beyond

By Harriet Lefton, Writer, TipRanks Oct 31, 2019

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

Revance Therapeutics Inc Is Set to Shake Up the Botox Market

By Chris Lau, InvestorPlace Contributor Apr 4, 2018

RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.